Why Women’s Health Needs Real-World Evidence: Endometriosis, Patient Journey and Digital Health

Table of Contents

Executive Introduction

Healthcare systems worldwide continue to face persistent evidence gaps in women’s health. Randomized controlled trials remain essential for establishing efficacy and safety, but they do not fully capture the complexity of routine care, diagnostic delays, fragmented pathways, treatment adherence, patient-reported outcomes, and long-term impact in real-world settings.

Endometriosis is a strong example of this disconnect. It affects an estimated 10% of women of reproductive age and is associated with chronic pelvic pain, infertility, fatigue, impaired quality of life, repeated healthcare utilization, and productivity loss.

The problem is not only biological. It is also systemic. Many patients spend years moving through disconnected healthcare encounters before receiving an accurate diagnosis. This diagnostic odyssey exposes a major limitation of traditional evidence models: they often explain whether an intervention works under controlled conditions, but they do not sufficiently explain how patients actually experience disease, access care, adhere to treatment, or move through healthcare systems.

Real-World Evidence (RWE), supported by patient journey data and digital health platforms, offers a complementary path. It can help healthcare leaders, Medical Affairs teams, HEOR professionals, policymakers, researchers, and innovators understand not only disease mechanisms, but also care delivery failures, access barriers, unmet needs, and implementation opportunities.

Problem Definition: The Diagnostic Delay in Endometriosis

Endometriosis is a chronic inflammatory condition characterized by the presence of endometrial-like tissue outside the uterus. Its clinical presentation is heterogeneous and may include dysmenorrhea, chronic pelvic pain, dyspareunia, infertility, fatigue, gastrointestinal symptoms, urinary symptoms, and psychological distress.

One of the most important challenges is diagnostic delay. Multiple studies report that women with endometriosis may wait several years between symptom onset and diagnosis. During this period, patients often consult different healthcare professionals, undergo repeated investigations, receive symptomatic or incomplete treatments, and experience progressive loss of trust in the healthcare system.

This delay is not a marginal issue. It has clinical, economic, social, and strategic consequences. Delayed diagnosis may be associated with prolonged suffering, increased healthcare utilization, work impairment, repeated emergency visits, productivity loss, and reduced health-related quality of life.

This issue is discussed further in our article on why endometriosis can take years to diagnose.

From a systems perspective, diagnostic delay represents a failure of pathway design. It reflects gaps in medical education, under-recognition of pelvic pain, fragmented referral networks, limited access to specialized imaging, normalization of menstrual pain, and insufficient patient-centered data.

Current Evidence Limitations

Randomized controlled trials are indispensable for evaluating efficacy and safety. However, they are not designed to answer several questions that matter in routine care.

In endometriosis, key unanswered questions include:

How long does it take for patients to receive a diagnosis in different healthcare settings?
Which symptoms are most commonly underestimated?
How many professionals do patients consult before diagnosis?
Which care pathways generate unnecessary delays?
What factors influence adherence to hormonal, surgical, or multidisciplinary treatments?
How does disease affect work, education, mental health, relationships, and quality of life over time?
Which subgroups are more vulnerable to diagnostic failure?

Traditional trials usually have strict inclusion criteria, limited follow-up periods, controlled environments, and predefined endpoints. These features strengthen internal validity, but they may reduce generalizability to heterogeneous real-world populations.

This creates an evidence gap between efficacy and effectiveness. In clinical trials, we may understand whether a therapy works under ideal conditions. In real life, we need to understand whether patients can access it, tolerate it, adhere to it, benefit from it, and remain engaged over time.

For a broader clinical and methodological perspective on diagnostic and treatment pathways in endometriosis, the ESHRE guideline remains one of the most relevant international references.

Strategic Implications for Healthcare Systems and Industry

The endometriosis evidence gap is not only a clinical problem. It is a strategic problem.

For healthcare systems, delayed diagnosis increases costs, reduces efficiency, and worsens patient outcomes. For policymakers, it reveals structural weaknesses in women’s health. For payers, it complicates value assessment. For Medical Affairs and HEOR teams, it limits the ability to generate meaningful evidence around unmet needs, patient burden, treatment pathways, and real-world outcomes.

For digital health companies and innovators, the lesson is equally clear: a digital solution that does not generate credible evidence will remain a tool, not an evidence infrastructure.

In women’s health, innovation cannot rely only on product development. It must also build mechanisms to understand real-world patient behavior, care navigation, symptom burden, engagement, and outcomes.

This is where patient journey research becomes strategically relevant.

The Role of Real-World Data and Real-World Evidence

Real-World Data refers to health-related data collected outside traditional randomized clinical trials. According to regulatory and methodological frameworks, Real-World Evidence can be generated from sources such as electronic health records, claims databases, registries, patient-reported outcomes, digital health platforms, wearable devices, and structured patient journey assessments.

When analyzed using appropriate scientific methods, these data can generate Real-World Evidence.

In endometriosis, RWE can help answer questions such as:

What is the average time from symptom onset to diagnosis?
Which care pathways are associated with faster diagnosis?
What is the burden of symptoms before diagnosis?
How often do patients use emergency or repeated outpatient services?
How do treatments perform in routine practice?
What are the main drivers of treatment discontinuation?
Which patient groups remain underserved?

For Medical Affairs and Evidence Generation teams, these insights are valuable because they support:

identification of unmet medical needs;
development of medical education strategies;
patient-centered evidence planning;
health technology assessment;
value demonstration;
stakeholder engagement;
real-world implementation strategies.

However, RWE must be methodologically rigorous. Observational data are vulnerable to confounding, missingness, selection bias, measurement error, and lack of standardization. Therefore, transparency, predefined analytical plans, validated instruments, and appropriate reporting standards are essential.

Patient Journey Data as a Strategic Evidence Source

Patient journey data provide a structured view of how individuals experience disease and interact with healthcare systems over time.

For endometriosis, patient journey research may capture:

age at symptom onset;
time to first medical consultation;
number and type of professionals consulted;
diagnostic tests performed;
imaging pathways;
treatment sequence;
symptom evolution;
quality of life impact;
work productivity impairment;
educational needs;
barriers to specialized care.

This kind of evidence is particularly relevant in women’s health because many conditions are underdiagnosed, undertreated, or normalized within social and clinical contexts.

Patient journey data can transform anecdotal experience into structured evidence. That transformation matters. It allows healthcare systems and industry stakeholders to move from “patients report delays” to “these are the measurable pathway failures, their frequency, their impact, and their potential intervention points.”

Digital Health as Evidence Infrastructure

Digital health platforms can support care, education, navigation, engagement, and data collection. Their strategic value increases when they are designed not only as interfaces, but as evidence infrastructures.

In endometriosis, digital platforms may support:

symptom tracking;
patient-reported outcome collection;
education modules;
care navigation;
longitudinal follow-up;
adherence monitoring;
engagement analytics;
population-level insights.

This creates a dual function. The platform supports patients while generating structured real-world data. If ethically governed and methodologically designed, this data can contribute to observational studies, implementation research, patient journey analysis, and evidence generation.

However, digital health implementation is not automatic. Common barriers include low engagement, poor integration into clinical workflows, limited interoperability, data quality problems, privacy concerns, digital exclusion, and lack of clinical validation. These challenges are discussed in greater detail in our analysis of why digital solutions for endometriosis often fail in practice.

Therefore, digital health in women’s health should not be evaluated only by downloads, access, or usability. It should also be evaluated for its ability to generate reliable, actionable, patient-centered evidence to support clinical care, healthcare planning, and decision-making.

EndoConnect: A Practical Example

EndoConnect was conceived as a digital health initiative focused on education, navigation, and support for women affected by endometriosis.

Beyond its educational role, it can serve as a framework for structured patient journey research and real-world evidence generation. A platform like EndoConnect may support data collection on diagnostic delay, symptom burden, healthcare utilization, educational gaps, engagement patterns, and patient-reported outcomes.

Potential evidence-generation questions include:

What is the diagnostic journey of women with suspected or confirmed endometriosis?
Which symptoms are associated with longer delays?
How many healthcare professionals are consulted before diagnosis?
What are the most common educational gaps?
How does digital education affect patient understanding and engagement?
Which patient-reported outcomes should be prioritized in future studies?

This approach illustrates a broader strategic principle: digital health tools should not be designed only as isolated interventions. They should be designed as learning systems capable of improving care while generating real-world insights.

Implications for Medical Affairs, RWE and Digital Health

For Medical Affairs, RWE can inform scientific narratives, educational strategies, stakeholder engagement, and identification of unmet needs.

For RWE and HEOR teams, patient journey data can support burden-of-disease analyses, outcomes research, value demonstration, and health technology assessment.

For digital health leaders, structured evidence generation can differentiate serious health platforms from superficial engagement tools.

For policymakers, patient journey evidence can identify system-level bottlenecks and guide pathway redesign.

For investors and innovators, the message is direct: in women’s health, the most valuable digital tools will not merely provide information. They will generate credible, longitudinal, patient-centered evidence.

Future Opportunities

Future strategies in women’s health should also consider evolving regulatory frameworks for Real-World Evidence, particularly as health systems increasingly seek evidence that reflects routine clinical practice and patient-centered outcomes.

The future of women’s health research should integrate clinical expertise, real-world data, patient-reported outcomes, implementation science, and digital platforms into a unified evidence-generation ecosystem.

Key opportunities include:

Prospective observational studies embedded within digital health platforms.
Standardized patient journey metrics for endometriosis and other chronic gynecological conditions.
Integration of patient-reported outcomes into routine clinical care.
Real-world assessment of diagnostic pathways and healthcare utilization patterns.
Pragmatic studies evaluating digital navigation and education tools.
AI-supported identification of diagnostic delay patterns and unmet needs.
Ethical governance frameworks for patient-generated data.
Collaborative models involving academia, healthcare systems, industry, regulators, and patient communities.

International initiatives led by organizations such as the FDA, EMA, and ISPOR increasingly recognize the strategic value of Real-World Evidence in complementing traditional clinical research and informing healthcare decision-making.

The goal is not to replace randomized controlled trials. Rather, it is to complement them with evidence that reflects the complexity, diversity, and variability of real-world clinical practice.

As women’s health continues to gain visibility among healthcare leaders, researchers, policymakers, and innovators, the ability to generate high-quality patient-centered evidence will become a critical differentiator for healthcare systems, digital health platforms, and evidence-generation programs.

Conclusion

Women’s health cannot be adequately understood through an evidence model centered exclusively on randomized trials. Endometriosis demonstrates why real-world data, patient journey research, and digital health platforms are increasingly necessary.

Diagnostic delay, fragmented care, symptom under-recognition, and unmet educational needs are not fully visible through traditional clinical research alone. They require evidence generated from the real conditions in which patients live, seek care, make decisions, and interact with healthcare systems.

Real-World Evidence offers a path toward more patient-centered, data-informed, and implementation-ready women’s health strategies.

For endometriosis, the opportunity is clear: transform fragmented patient experiences into structured evidence, and transform digital tools into learning systems that improve care while generating insight.

That is the next frontier for women’s health innovation.

About the Author

Dr. Kelnner Portela Luz, MD, MSc, is a physician, radiologist, and researcher focused on Women’s Health, Digital Health, Real-World Evidence, patient journey research, and healthcare innovation. He is the founder of EndoConnect and creator of Endora Insights.

Suggested References

Zondervan KT, Becker CM, Missmer SA. Endometriosis. New England Journal of Medicine. 2020;382:1244–1256.
Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Human Reproduction Open. 2022.
World Health Organization. Endometriosis. WHO Fact Sheet.
Nnoaham KE, Hummelshoj L, Webster P, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertility and Sterility. 2011;96(2):366–373.
Soliman AM, Fuldeore M, Snabes MC. Factors associated with time to endometriosis diagnosis in the United States. Journal of Women’s Health. 2017.
Fuldeore MJ, Soliman AM. Prevalence and symptomatic burden of diagnosed endometriosis in the United States. Journal of Women’s Health. 2017.
U.S. Food and Drug Administration. Framework for FDA’s Real-World Evidence Program. 2018.
Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness. Pharmacoepidemiology and Drug Safety. 2017;26(9):1033–1039.
Wang SV, Schneeweiss S, Berger ML, et al. Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies. Value in Health. 2017;20(8):1009–1022.
ISPOR. Real-World Evidence Special Interest Group resources and good practice reports.